A Public Health Antibody Screening Indicates a 6-Fold Higher SARS-CoV-2 Exposure Rate than Reported Cases in Children.

Autor:	Hippich M; Institute of Diabetes Research, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich-Neuherberg, Germany.; German Center for Diabetes Research (DZD), Munich, Germany., Holthaus L; German Center for Diabetes Research (DZD), Munich, Germany.; Institute for Diabetes and Obesity, Helmholtz Diabetes Center at Helmholtz Zentrum München, Munich-Neuherberg, Germany., Assfalg R; Forschergruppe Diabetes, Technical University Munich at Klinikum rechts der Isar, Munich, Germany., Zapardiel-Gonzalo J; Institute of Diabetes Research, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich-Neuherberg, Germany., Kapfelsperger H; Institute of Diabetes Research, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich-Neuherberg, Germany., Heigermoser M; Institute of Diabetes Research, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich-Neuherberg, Germany., Haupt F; Institute of Diabetes Research, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich-Neuherberg, Germany., Ewald DA; Berufsverband der Kinder und Jugendärzte e.V., Landesverband Bayern, Regensburg, Germany., Welzhofer TC; Forschergruppe Diabetes, Technical University Munich at Klinikum rechts der Isar, Munich, Germany., Marcus BA; Forschergruppe Diabetes, Technical University Munich at Klinikum rechts der Isar, Munich, Germany., Heck S; Institute of Diabetes Research, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich-Neuherberg, Germany., Koelln A; Institute of Diabetes Research, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich-Neuherberg, Germany., Stock J; Institute of Diabetes Research, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich-Neuherberg, Germany., Voss F; Institute of Diabetes Research, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich-Neuherberg, Germany., Secchi M; Diabetes Research Institute, IRCCS San Raffaele Scientific Institute, via Olgettina 60, 20132 Milano, Italy., Piemonti L; Diabetes Research Institute, IRCCS San Raffaele Scientific Institute, via Olgettina 60, 20132 Milano, Italy., de la Rosa K; Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany., Protzer U; Institute of Virology, Technical University Munich and Helmholtz Zentrum München, Neuherberg, Germany.; Deutsches Zentrum für Infektionsforschung (DZIF), Munich partner site, Braunschweig, Germany., Boehmer M; Bavarian Health and Food Safety Authority, Oberschleißheim, Germany.; Institute of Social Medicine and Health Systems Research, Otto-von-Guericke-University, Magdeburg, Germany., Achenbach P; Institute of Diabetes Research, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich-Neuherberg, Germany.; German Center for Diabetes Research (DZD), Munich, Germany.; Forschergruppe Diabetes, Technical University Munich at Klinikum rechts der Isar, Munich, Germany.; Forschergruppe Diabetes e.V. at Helmholtz Zentrum München, German Research Center for Environmental Health, Munich-Neuherberg, Germany., Lampasona V; Diabetes Research Institute, IRCCS San Raffaele Scientific Institute, via Olgettina 60, 20132 Milano, Italy., Bonifacio E; Technische Universität Dresden, Center for Regenerative Therapies Dresden, Dresden, Germany.; Paul Langerhans Institute Dresden of the Helmholtz Center Munich at University Hospital Carl Gustav Carus and Faculty of Medicine, TU Dresden, Germany., Ziegler AG; Institute of Diabetes Research, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich-Neuherberg, Germany.; German Center for Diabetes Research (DZD), Munich, Germany.; Forschergruppe Diabetes, Technical University Munich at Klinikum rechts der Isar, Munich, Germany.; Forschergruppe Diabetes e.V. at Helmholtz Zentrum München, German Research Center for Environmental Health, Munich-Neuherberg, Germany.
Jazyk:	angličtina
Zdroj:	Med (New York, N.Y.) [Med] 2021 Feb 12; Vol. 2 (2), pp. 149-163.e4. Date of Electronic Publication: 2020 Oct 29.
DOI:	10.1016/j.medj.2020.10.003
Abstrakt:	Background: Antibody responses to virus reflect exposure and potential protection. Methods: We developed a highly specific and sensitive approach to measuring antibodies against SARS-CoV-2 for population-scale immune surveillance. Antibody positivity was defined as a dual-positive response against both the receptor-binding domain and nucleocapsid proteins of SARS-CoV-2. Antibodies were measured by immunoprecipitation assays in capillary blood from 15,771 children aged 1 to 18 years living in Bavaria, Germany, and participating in a public health type 1 diabetes screening program (ClinicalTrials.gov: NCT04039945), in 1,916 dried blood spots from neonates in a Bavarian screening study (ClinicalTrials.gov: NCT03316261), and in 75 SARS-CoV-2-positive individuals. Virus positive incidence was obtained from the Bavarian health authority data. Findings: Dual-antibody positivity was detected in none of the 3,887 children in 2019 (100% specificity) and 73 of 75 SARS-CoV-2-positive individuals (97.3% sensitivity). Antibody surveillance in children during 2020 resulted in frequencies of 0.08% in January to March, 0.61% in April, 0.74% in May, 1.13% in June, and 0.91% in July. Antibody prevalence from April 2020 was 6-fold higher than the incidence of authority-reported cases (156 per 100,000 children), showed marked variation between the seven Bavarian regions (p < 0.0001), and was not associated with age or sex. Transmission in children with virus-positive family members was 35%. 47% of positive children were asymptomatic. No association with type 1 diabetes autoimmunity was observed. Antibody frequency in newborns was 0.47%. Conclusions: We demonstrate the value of population-based screening programs for pandemic monitoring. Funding: The work was supported by funding from the BMBF (FKZ01KX1818). Competing Interests: The authors declare no competing interests. (© 2020 Elsevier Inc.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu